Anti-CD19 Market size was valued at USD 4.5 Billion in 2024 and is forecasted to grow at a CAGR of 9.9% from 2026 to 2033, reaching USD 10.2 Billion by 2033.
The Anti-CD19 market in Malaysia is witnessing significant growth, driven by the rising prevalence of B-cell malignancies and advancements in CAR-T cell therapies. CD19, a protein expressed on B cells, has become a pivotal target in treating various hematologic cancers, leading to the development of innovative therapies that are reshaping the country's oncology landscape.
Leading the charge is Bristol-Myers Squibb's BREYANZI (lisocabtagene maraleucel), an autologous CAR T-cell therapy approved for multiple indications, including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Mantle Cell Lymphoma (MCL). In 2024, BREYANZI reported sales of USD 747 million, reflecting its growing acceptance in the medical community. Its mechanism involves targeting CD19, a protein expressed on B cells, offering a tailored approach to cancer treatment. citeturn0search0
The global CAR T-cell therapy market is projected to escalate from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, at a compound annual growth rate (CAGR) of 39.6%. This surge is attributed to technological advancements and increased investments in the sector. Notably, CD19-targeted therapies are expected to play a significant role in this expansion. citeturn0search1
In Malaysia, the demand for Anti-CD19 therapies is influenced by several industry requirements:
Regulatory Compliance: Adhering to Malaysia's stringent regulatory standards is crucial for the approval and commercialization of Anti-CD19 therapies. Companies must navigate complex approval processes to ensure patient safety and efficacy.
Manufacturing Capabilities: The production of CAR T-cell therapies like BREYANZI requires sophisticated facilities and stringent quality controls. Establishing such infrastructure is vital to meet the growing demand and maintain treatment consistency.
Healthcare Infrastructure: Adequate healthcare facilities equipped with the necessary technology and trained personnel are essential for the administration and monitoring of CAR T-cell therapies. Enhancing these infrastructures will facilitate broader adoption of Anti-CD19 treatments.
Despite the promising outlook, challenges persist. The high cost of CAR T-cell therapies poses a barrier to widespread adoption, necessitating strategies to make treatments more affordable. Additionally, the complexity of manufacturing and supply chain logistics can impact the timely delivery of these therapies to patients. citeturn0search8
In conclusion, Malaysia's Anti-CD19 market is poised for growth, driven by innovative therapies and increasing industry focus. Addressing regulatory, manufacturing, and infrastructural challenges will be pivotal in harnessing the full potential of these life-saving treatments.
Get an In-Depth Research Analysis of the Malaysia Anti-CD19 Market Size And Forecast [2025-2032]
Â
Thermo Fisher Scientific
R & D Systems
Bio-Rad
LifeSpan BioSciences
Abbexa Ltd
Boster Bio
Aviva Systems Biology
Biobyt
Genetex
ProteoGenix
Â
By 2030, Malaysia is expected to witness significant momentum in the market research industry, aligning with the global projection of surpassing $120 billion, driven by a compound annual growth rate (CAGR) of over 5.8% from 2023 to 2030. The industry in Malaysia is being reshaped by technological disruptions, particularly through the adoption of machine learning, artificial intelligence, and advanced data analytics. These technologies provide businesses with predictive analysis and real-time consumer insights, enabling smarter and more precise decision-making. As part of the broader Asia-Pacific region, Malaysia is positioned to contribute substantially to the over 35% revenue growth expected from this region. Additionally, the adoption of innovative techniques such as mobile surveys, social listening, and online panels is rapidly gaining ground in Malaysia, emphasizing speed, precision, and customization, and driving a new era of data-driven strategies across industries.
Â
Get Discount On The Purchase of the Malaysia Anti-CD19 Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Malaysia Anti-CD19 Market
Monoclonal Antibodies
CAR T-Cell Therapies
BiSpecific T-Cell Engagers (BiTEs)
Small Molecule Inhibitors
Acute Lymphoblastic Leukemia (ALL)
B-Cell Non-Hodgkin Lymphomas (NHL)
Chronic Lymphocytic Leukemia (CLL)
Other Hematological Malignancies
Hospitals
Oncology Clinics
Research Institutions
Pharmaceutical Companies
Direct Sales
Distributors
Online Pharmacies
Retail Pharmacies
Intravenous (IV)
Subcutaneous
Intramuscular
1. Singapore
Relationship: Strong economic ties; major trading partner.
Highlights: Advanced financial and logistics hub; shares deep cross-border business and travel links with Malaysia.
2. Indonesia
Relationship: Largest ASEAN economy; close cultural and linguistic ties.
Highlights: Major market for Malaysian exports; shared initiatives in palm oil, labor, and regional security.
3. Thailand
Relationship: Land-border neighbor with active cross-border trade.
Highlights: Strong tourism, agricultural, and automotive collaboration.
4. Brunei
Relationship: Close diplomatic and energy-sector ties.
Highlights: Joint ventures in oil & gas; similar Malay cultural heritage.
5. Philippines
Relationship: Regional partner in ASEAN; maritime neighbor.
Highlights: Collaborations in education, labor migration, and disaster relief.
6. Vietnam
Relationship: Growing trade and investment partner.
Highlights: Rising manufacturing hub; strong demand for Malaysian technology and services.
7. Cambodia, Laos, and Myanmar
Relationship: Developing ASEAN members with growing economic ties to Malaysia.
Highlights: Opportunities in construction, retail, and financial services.
For More Information or Query, Visit @ Malaysia Anti-CD19 Market Research Analysis
1. Introduction of the Malaysia Anti-CD19 Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Malaysia Anti-CD19 Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Malaysia Anti-CD19 Market, By Type
6. Malaysia Anti-CD19 Market, By Application
7. Malaysia Anti-CD19 Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia
Vietnam
8. Malaysia Anti-CD19 Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/